Back to Best of AC17 Session - Management of Hodgkin Lymphoma Status post Autologous Hematopoietic Stem Cell Transplantation - On-Demand
Best of AC17 Session - Management of Hodgkin Lymphoma Status post Autologous Hematopoietic Stem Cell Transplantation - On-Demand

Best of AC17 Session - Management of Hodgkin Lymphoma Status post Autologous Hematopoietic Stem Cell Transplantation - On-Demand

Although aHSCT is the standard of care for patients with relapsed HL, only about 50% of these patients will be cured. Patients who relapse or have progressive disease after aHSCT have a very poor prognosis. This session will focus on risk factors associated with disease relapse following aHSCT and the use of brentuximab vedotin as consolidation treatment in high-risk patients. The use of novel agents such as PD-1 inhibitors in patients who relapse post aHSCT will also be discussed.

 

Content Area: Patient Management & Therapeutics

Product Details

Management of Hodgkin Lymphoma Status Post Autologous Hematopoietic Stem Cell Transplantation

 

Speaker: Sandra Horowitz, PharmD

 

Learning Objectives:

1.      Identify risk factors associated with relapse after autologous hematopoietic stem cell transplant (aHSCT) in patients with Hodgkin lymphoma (HL).

2.      Review the role of consolidation therapy with brentuximab vedotin status post aHSCT.

3.      Describe novel treatments for patients with relapsed HL status post aHSCT.

 

  • List Price: $35.00 USD
  • Member Price: $25.00 USD
Join and Save!
Log into see if you qualify for a lower price.
HOPA members save $10.00 USD or more!
Become a member